FDA Approves GlaxoSmithKilne’s Triple Trelega Ellipta Inhaler
The FDA has approved the triple inhaler developed by GlaxoSmithKline and Innoviva to treat chronic obstructive pulmonary disease.
The Trelega Ellipta dry powder inhaler uses fluticasone furoate, umeclidinium and vilanterol to help adults with COPD manage the condition. The device is the first once-daily product approved in the U.S. that combines three active molecules in a single inhaler for COPD patients.
Last week, an EMA panel recommended approval for the Trelegy Ellipta triple-combination inhaler.